- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02536833
A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- Research Site
-
-
Arizona
-
Phoenix, Arizona, United States, 85029
- Research Site
-
Tucson, Arizona, United States, 85712
- Research Site
-
-
California
-
El Cajon, California, United States, 92020
- Research Site
-
Rancho Mirage, California, United States, 92270
- Research Site
-
Spring Valley, California, United States, 91978
- Research Site
-
-
Colorado
-
Denver, Colorado, United States, 80230
- Research Site
-
-
Florida
-
Clearwater, Florida, United States, 33761
- Research Site
-
Coral Gables, Florida, United States, 33134
- Research Site
-
Jacksonville, Florida, United States, 32216
- Research Site
-
Miami, Florida, United States, 33173
- Research Site
-
West Palm Beach, Florida, United States, 33409
- Research Site
-
-
Georgia
-
Woodstock, Georgia, United States, 30189
- Research Site
-
-
Kansas
-
Newton, Kansas, United States, 67114
- Research Site
-
Wichita, Kansas, United States, 67205
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40504
- Research Site
-
-
Maryland
-
Frederick, Maryland, United States, 21702
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Research Site
-
Worcester, Massachusetts, United States, 01605
- Research Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Research Site 1
-
Saint Louis, Missouri, United States, 63141
- Research Site 2
-
-
New York
-
Orchard Park, New York, United States, 14127
- Research Site
-
Rochester, New York, United States, 14609
- Research Site
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Research Site
-
Salisbury, North Carolina, United States, 28144
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45246
- Research Site
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Research Site
-
-
South Carolina
-
Mount Pleasant, South Carolina, United States, 29464
- Research Site
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57702
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37912
- Research Site
-
-
Texas
-
Austin, Texas, United States, 78745
- Research Site
-
Houston, Texas, United States, 77074
- Research Site
-
-
Utah
-
West Layton, Utah, United States, 84041
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, United States, 22911
- Research Site
-
Richmond, Virginia, United States, 23225
- Research Site
-
-
Wisconsin
-
Franklin, Wisconsin, United States, 53132
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females between 40 and 80 years of age, inclusive, in general good health
- Ambulatory (single assistive devices such as canes allowed if needed less than 50% of the time, subjects requiring a walker are excluded)
- Established diagnosis of primary femorotibial OA in the target knee by standard American College of Rheumatology (ACR) criteria for at least 6 months (clinical AND radiographic criteria); if bilateral knee OA is present, the target knee is defined as the knee with greater pain at screening based on the subject's evaluation and the Investigator's clinical judgment
- Radiographic disease Stage 2 or 3 in the target knee according to the Kellgren-Lawrence grading of knee OA as assessed by independent central readers
- Screening pain visual analog scale (VAS) score of 30-80 mm (on a scale of 0-100 mm) for the target knee while on symptomatic oral treatment at screening (if the subject requires oral treatment)
- Total WOMAC score of 72-192 (out of 240) for the target knee while on symptomatic oral treatment at screening (if the subject requires oral treatment)
Willingness to omit the following for 24 hours prior to all Study Visits, excluding the Screening Visit:
- Pain medications
- Medications or supplements for the treatment of OA
- Participation in a formalized in-office and/or supervised OA disease program (e.g., a prescribed patient education program, physiotherapy, etc.)
- Full understanding of the requirements of the study and willingness to comply with all study visits and assessments
- Subjects must have read and understood the informed consent form, and must have signed it prior to any study-related procedure being performed
- Subject's Day 1 visit must occur while enrollment into the study is open
Exclusion Criteria:
- Women who are pregnant or lactating
- Women of childbearing potential (i.e., who are not surgically sterile or postmenopausal as defined by no menstrual periods for 12 consecutive months and no other biological or physiological cause for amenorrhea can be identified); males who are sexually active and have a partner who is capable of becoming pregnant, neither of which have had surgery to become sterilized, who are not using an effective method of birth control (e.g., surgically-implanted hormonal therapy, intrauterine devices or oral birth control with barrier method)
- Body mass index (BMI) >40
- Partial or complete joint replacement in the target knee
- Previous exposure to SM04690
- Major surgery (e.g., interventional arthroscopy) in the target knee within 52 weeks prior to any study injection
- Any planned or elective surgery during the study period
- Significant and clinically evident misalignment of the target knee that would impact subject function, as determined by the Investigator
- History of malignancy within the last 5 years; however, subjects with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Subjects with other malignancies are eligible if they have been continuously disease free for at least 5 years prior to any study injection
- Clinically significant abnormal Screening Visit hematology values, blood chemistry values, HbA1c, or urinalysis values as determined by the investigator
- Any condition, including laboratory findings (not included in the Screening Visit laboratory tests) and findings in the medical history or in the pre-study assessments, that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
- Comorbid conditions that could affect pain assessment of the target knee, including, but not limited to, inflammatory rheumatic conditions such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, diabetic neuropathy, pseudogout, gout, and fibromyalgia
- Other conditions that, in the opinion of the Investigator, could affect pain assessment of the target knee, including, but not limited to, symptomatic hip osteoarthritis and symptomatic degenerative disc disease
- Any diagnosed psychiatric condition that includes, but is not limited to, a history of mania, bipolar disorder, psychotic disorder, schizophrenia, major depressive disorder, or generalized anxiety disorder
- Participation in a clinical research trial that included the receipt of an investigational product or any experimental therapeutic procedure within 12 weeks prior to any study injection; the last date of participation in the trial, not the last date of receipt of investigational product, must be at least 12 weeks prior to Study Visit Day 1
- Treatment of the target knee with systemic or intra-articular corticosteroids (e.g., methylprednisolone) within 8 weeks prior to Study Visit Day 1
- Viscosupplementation (e.g., hyaluronic acid) in the target knee within 24 weeks prior to Study Visit Day 1
- Effusion of the target knee clinically requiring aspiration within 12 weeks prior to Study Visit Day 1
- Use of electrotherapy, acupuncture, and/or chiropractic treatments for knee OA within 4 weeks prior to Study Visit Day 1
- Any known active infections, including suspicion of intra-articular infection, hepatitis B or hepatitis C infection, and/or infections that may compromise the immune system such as human immunodeficiency virus (HIV)
- Subjects taking prescription medications for OA who have not maintained a stable therapeutic regimen for a minimum of 12 weeks prior to Study Visit Day 1
Subjects requiring the chronic use (i.e., regular and consistent use for ≥ 12 weeks) of the medications listed below within 12 weeks prior to Study Visit Day 1:
- Opioids, both oral (e.g., tramadol) or transdermal (e.g., fentanyl patches) formulations
- Centrally acting analgesics (e.g., duloxetine)
- Glucocorticoids (e.g., methylprednisolone) administered by any route, with exception of inhaled, intranasal, and ophthalmic solutions
Any chronic condition that has not been well controlled or subjects with a chronic condition who have not maintained a stable therapeutic regimen of a prescription therapy for a minimum of 12 weeks prior to Study Visit Day 1. In addition, the following subjects will be excluded:
- Subjects with a baseline HbA1c >9
- Subjects with uncontrolled hypertension in the opinion of the investigator
- Subjects with symptomatic coronary artery disease in the opinion of the investigator
- Subjects who have a current or pending disability claim, workers' compensation, or litigation(s) that may compromise response to treatment
- Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative site, or are directly affiliated with the study at the investigative site
- Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 0.03 mg SM04690
Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension
|
|
Experimental: 0.07 mg SM04690
Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension
|
|
Experimental: 0.23 mg SM04690
Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension
|
|
Placebo Comparator: Placebo
Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline Osteoarthritis (OA) Pain in the Target Knee
Time Frame: Baseline and Week 13
|
Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 13.
The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints.
Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function).
The WOMAC Pain subscore is reported ranging from 0 to 100.
|
Baseline and Week 13
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline OA Pain in the Target Knee
Time Frame: Baseline and Week 26
|
Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 26.
The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints.
Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function).
The WOMAC Pain subscore is reported ranging from 0 to 100.
|
Baseline and Week 26
|
Change From Baseline OA Function in the Target Knee
Time Frame: Baseline and Week 13
|
Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 13.
The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints.
Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function).
The WOMAC Function subscore is reported ranging from 0 to 100.
|
Baseline and Week 13
|
Change From Baseline OA Function in the Target Knee
Time Frame: Baseline and Week 26
|
Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 26.
The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints.
Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function).
The WOMAC Function subscore is reported ranging from 0 to 100.
|
Baseline and Week 26
|
Change From Baseline OA Disease Activity as Assessed by the Patient
Time Frame: Baseline and Week 13
|
Change from baseline OA disease activity as assessed by the Patient Global Assessment at Week 13.
The Patient Global Assessment was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology.
The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her.
The VAS scale was anchored by "Very Well" on the left (scored as 0) and "Very Poorly" on the right (scored as 100).
Higher scores indicated poorer disease assessment by the subject.
|
Baseline and Week 13
|
Change From Baseline OA Disease Activity as Assessed by the Patient
Time Frame: Baseline and Week 26
|
Change from baseline OA disease activity as assessed by the Patient Global Assessment at Week 26.
The Patient Global Assessment was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology.
The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her.
The VAS scale was anchored by "Very Well" on the left (scored as 0) and "Very Poorly" on the right (scored as 100).
Higher scores indicated poorer disease assessment by the subject.
|
Baseline and Week 26
|
Change From Baseline in Medial Joint Space Width of Target Knee
Time Frame: Baseline and Week 26
|
Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 26.
|
Baseline and Week 26
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline OA Pain in the Target Knee
Time Frame: Baseline and Week 52
|
Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 52.
The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints.
Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function).
The WOMAC Pain subscore is reported ranging from 0 to 100.
|
Baseline and Week 52
|
Change From Baseline OA Function in the Target Knee
Time Frame: Baseline and Week 52
|
Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 52.
The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints.
Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function).
The WOMAC Function subscore is reported ranging from 0 to 100.
|
Baseline and Week 52
|
Change From Baseline in Medial Joint Space Width of Target Knee
Time Frame: Baseline and Week 52
|
Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 52.
|
Baseline and Week 52
|
Change From Baseline OA Pain in the Target Knee [Unilateral Symptomatic OA]
Time Frame: Baseline and Week 52
|
Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 52.
The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints.
Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function).
The WOMAC Pain subscore is reported ranging from 0 to 100.
|
Baseline and Week 52
|
Change From Baseline OA Function in the Target Knee [Unilateral Symptomatic OA]
Time Frame: Baseline and Week 52
|
Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 52.
The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints.
Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function).
The WOMAC Function subscore is reported ranging from 0 to 100.
|
Baseline and Week 52
|
Change From Baseline in Medial Joint Space Width of Target Knee [Unilateral Symptomatic OA]
Time Frame: Baseline and Week 52
|
Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 52.
|
Baseline and Week 52
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SM04690-OA-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States